XML 20 R13.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Supplementary Balance Sheet Information | 3 Months Ended
--- | ---
Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract] |
Supplementary Balance Sheet Information | Note 5 – Supplementary Balance Sheet Information Property and equipment consist of the following (in thousands):
|  | As of |
|  | March 31, 2024 |  |  | December 31, 2023 |
Lab equipment |  | $ | 6,100 |  |  | $ | 6,089 |
Leasehold improvements |  |  | 26,262 |  |  |  | 24,713 |
Computer equipment |  |  | 1,225 |  |  |  | 1,221 |
Furniture and fixtures |  |  | 1,067 |  |  |  | 1,034 |
Software |  |  | 325 |  |  |  | 325 |
Vehicles |  |  | 97 |  |  |  | 97 |
Construction in process |  |  | 32 |  |  |  | — |
|  |  | 35,108 |  |  |  | 33,479 |
Less accumulated depreciation |  |  | (6,533 | ) |  |  | (5,612 | )
Total property and equipment, net |  | $ | 28,575 |  |  | $ | 27,867 |
Depreciation expense for the three months ended March 31, 2024 and 2023 was $0.9 million and $0.3 million, respectively. Intangible assets, excluding goodwill, consist of the following (in thousands):
|  | March 31, 2024 |  |  | December 31, 2023 |
|  | Cost |  |  | Accumulated Amortization |  |  | Net Carrying Value |  |  | Cost |  |  | Accumulated Amortization |  |  | Net Carrying Value |
Intangible assets subject to amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Patents |  | $ | 1,946 |  |  | $ | (782 | ) |  | $ | 1,164 |  |  | $ | 1,975 |  |  | $ | (752 | ) |  | $ | 1,223 |
Purchased technology |  |  | 16,900 |  |  |  | (10,797 | ) |  |  | 6,103 |  |  |  | 16,900 |  |  |  | (10,328 | ) |  |  | 6,572 |
Intangible assets not subject to amortization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trademarks |  |  | 117 |  |  |  | — |  |  |  | 117 |  |  |  | 116 |  |  |  | — |  |  |  | 116 |
Total |  | $ | 18,963 |  |  | $ | (11,579 | ) |  | $ | 7,384 |  |  | $ | 18,991 |  |  | $ | (11,080 | ) |  | $ | 7,911 |
Amortization expense related to definite-lived intangible assets was $0.5 million for both the three months ended March 31, 2024 and 2023, respectively. Future estimated amortization expense of intangible assets is (in thousands):
|  | As of March 31, 2024 |
Remainder of 2024 |  | $ | 1,511 |
2025 |  |  | 2,011 |
2026 |  |  | 1,992 |
2027 |  |  | 1,033 |
2028 |  |  | 85 |
2029 and thereafter |  |  | 635 |
Total |  | $ | 7,267 |
Accrued liabilities consist of the following (in thousands):
|  | As of |
|  | March 31, 2024 |  |  | December 31, 2023 |
Compensation related accruals |  | $ | 3,471 |  |  | $ | 3,855 |
Accrued clinical trial expense |  |  | 969 |  |  |  | 983 |
Other expenses |  |  | 3,458 |  |  |  | 2,872 |
Total accrued liabilities |  | $ | 7,898 |  |  | $ | 7,710 |

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration